A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin

Other

(3586) Views  (886) Full article downloads

Authors: Eddy Anglade, Launa J Aspeslet, Sidney L Weiss

Published Date December 2008 Volume 2008:2(4) Pages 693 - 702

DOI: http://dx.doi.org/10.2147/OPTH.S2452

Eddy Anglade¹, Launa J Aspeslet², Sidney L Weiss¹

¹Lux Biosciences Inc., Jersey City, NJ, USA; ²Isotechnika Inc., Edmonton, AB, Canada

Abstract: Uveitis is an inflammatory, putative Th1-mediated autoimmune disease that affects various parts of the eye and is a leading cause of visual loss. Currently available therapies are burdened with toxicities and/or lack definitive evidence of efficacy. Voclosporin, a rationally designed novel calcineurin inhibitor, exhibits a favorable safety profile, a strong correlation between pharmacokinetic and pharmacodynamic response, and a wide therapeutic window. The LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to TrEatment) clinical development program was initiated in 2007 to assess the safety and efficacy of voclosporin for the treatment, maintenance, and control of all forms of noninfectious uveitis. If LUMINATE is successful, voclosporin will become the first Food and Drug Administration-approved corticosteroid-sparing agent for this condition.

Keywords: voclosporin, calcineurin inhibitors, LX211, LUMINATE trials, ophthalmic diseases, uveitis, ISA247